Limin Vincent Shi

Dr. Limin Vincent Shi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2016 in International Journal of Food Science and Technology
Verified
Journal Article
Closed access
PDF file
BLBo Liu
Bo Liu
TYTao Yang
Tao Yang
LZLinna Zeng
Linna Zeng
Limin Vincent ShiLimin Vincent Shi
Limin Vincent Shi
YLYan Li
Yan Li
Feijun LuoFeijun Luo
Feijun Luo

1 March 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
SLSiman Liu
Siman Liu
Zhipeng (Toby) TaoZhipeng (Toby) Tao
Zhipeng (Toby) Tao
MQMingyu Qiao
Mingyu Qiao
Limin Vincent ShiLimin Vincent Shi
Limin Vincent Shi
Background: Gut microbiomes play a vital role in maintaining whole-body metabolic homeostasis. It has gained significant attention in recent years due to advancements in genome sequencing technologies and a deeper understanding of its relationship with obesity. However, the specific ways in which different microorganisms directly or indirectly influence host obesity, as well as the underlying mechanisms, remain uncertain because of the complexity of gut microbiota composition. Methods: In this review, we summarize the roles of the major gut microbiota phyla such as Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobia in obesity and type 2 diabetes based on studies published in the past five years on PubMed and Google Scholar. The current therapeutic strategies associated with gut microbiota are also explored from clinical trials, and challenges and future directions are discussed. Results and Conclusions: This review will provide a deeper understanding of the functions of major gut microbiota in obesity and type 2 diabetes, which could lead to more individualized and effective treatments for metabolic diseases.

12 March 2024 in Clinical Science
Verified
Journal Article
Open access
PDF file
Limin Vincent ShiLimin Vincent Shi
Limin Vincent Shi
JYJinying Yang
Jinying Yang
Zhipeng (Toby) TaoZhipeng (Toby) Tao
Zhipeng (Toby) Tao
LZLouise Zheng
Louise Zheng
TBTyler F. Bui
Tyler F. Bui
ZCZhiyong Cheng
Zhiyong Cheng
Browning of white adipose tissue is hallmarked by increased mitochondrial density and metabolic improvements. However, it remains largely unknown how mitochondrial turnover and quality control are regulated during adipose browning. In the present study, we found that mice lacking adipocyte FoxO1, a transcription factor that regulates autophagy, adopted an alternate mechanism of mitophagy to maintain mitochondrial turnover and quality control during adipose browning. Post-developmental deletion of adipocyte FoxO1 (adO1KO) suppressed Bnip3 but activated Fundc1/Drp1/OPA1 cascade, concurrent with up-regulation of Atg7 and CTSL. In addition, mitochondrial biogenesis was stimulated via the Pgc1α/Tfam pathway in adO1KO mice. These changes were associated with enhanced mitochondrial homeostasis and metabolic health (e.g., improved glucose tolerance and insulin sensitivity). By contrast, silencing Fundc1 or Pgc1α reversed the changes induced by silencing FoxO1, which impaired mitochondrial quality control and function. Ablation of Atg7 suppressed mitochondrial turnover and function, causing metabolic disorder (e.g., impaired glucose tolerance and insulin sensitivity), regardless of elevated markers of adipose browning. Consistently, suppression of autophagy via CTSL by high-fat diet was associated with a reversal of adO1KO-induced benefits. Our data reveal a unique role of FoxO1 in coordinating mitophagy receptors (Bnip3 and Fundc1) for a fine-tuned mitochondrial turnover and quality control, underscoring autophagic clearance of mitochondria as a prerequisite for healthy browning of adipose tissue.